Document Detail

Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial.
MedLine Citation:
PMID:  11298545     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A previously reported randomized clinical trial showed treatment of Bowen's disease using photodynamic therapy (PDT) with topically applied delta-aminolaevulinic acid (ALA) to be at least as effective as cryosurgery and to be associated with fewer adverse effects. OBJECTIVES: To compare ALA-PDT and cryotherapy in the treatment of histopathologically verified basal cell carcinomas (BCCs) in a non-blinded, prospective phase III clinical trial. METHODS: One lesion from each of 88 patients was included. The BCCs were divided into superficial and nodular lesions. The follow-up period was restricted to 1 year with close follow-up for the first 3 months. Efficacy was assessed as the recurrence rate 12 months after the first treatment session, verified by histopathology. Tolerability was evaluated as the time of healing, pain and discomfort during and after the treatment, and final cosmetic outcome. RESULTS: Histopathologically verified recurrence rates in the two groups were statistically comparable and were 25% (11 of 44) for ALA-PDT and 15% (six of 39) for cryosurgery. However, clinical recurrence rates were only 5% (two of 44) for PDT and 13% (five of 39) for cryosurgery. Additional treatments, usually one, had to be performed in 30% of the lesions in the PDT group. The healing time was considerably shorter and the cosmetic outcome significantly better with PDT. Pain and discomfort during the treatment session and in the following week were low, and were equivalent with the two treatment modalities. CONCLUSIONS: In terms of efficacy, ALA-PDT is comparable with cryosurgery as a treatment modality for BCCs. Retreatments are more often required with PDT than with cryosurgery. This can easily be performed due to the shorter healing time, less scarring and better cosmetic outcome that follows ALA-PDT.
I Wang; N Bendsoe; C A Klinteberg; A M Enejder; S Andersson-Engels; S Svanberg; K Svanberg
Related Documents :
25492845 - Forms of self-criticising/attacking & self-reassuring scale: psychometric properties an...
22964475 - A randomized clinical trial of the effects of supplemental calcium and vitamin d3 on th...
21833945 - Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel...
21561395 - Recent developments in the treatment of osteoarthritis with nsaids.
2190565 - Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. curr...
17202005 - State affective instability in borderline personality disorder assessed by ambulatory m...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of dermatology     Volume:  144     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-04-12     Completed Date:  2001-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  832-40     Citation Subset:  IM    
Departments of Oncology and Dermatology and Venereology, Lund University Hospital, SE-221 85 Lund, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Basal Cell / drug therapy*,  pathology,  surgery*
Cryosurgery* / adverse effects
Follow-Up Studies
Middle Aged
Neoplasm Recurrence, Local
Photochemotherapy* / adverse effects,  methods
Prospective Studies
Skin Neoplasms / drug therapy*,  pathology,  surgery*
Treatment Outcome
Wound Healing

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.
Next Document:  Analysis of p53 and BAX mutations, loss of heterozygosity, p53 and BCL2 expression and apoptosis in ...